科伦博泰生物（SKB BIO）的合作方Windward Bio近日宣布，其用于治疗慢性阻塞性肺病（COPD）的候选药物SKB378/Win378，已在名为“Sirius”的第二期临床研究中完成了对首批患者的给药。
这一进展标志着该创新疗法在临床开发道路上迈出了关键一步。Sirius研究旨在评估SKB378/Win378在COPD患者中的安全性、耐受性及初步疗效，为后续的临床开发决策提供重要数据支持。慢性阻塞性肺病作为一种常见的、进行性发展的呼吸系统疾病，全球患者群体庞大，对新型有效治疗手段存在迫切需求。
此次研究的启动，是基于此前临床前及早期临床研究中观察到的积极信号。Windward Bio与科伦博泰生物的合作，整合了双方在药物研发领域的专业优势，共同推进该候选药物的开发进程。业界将密切关注此项二期临床试验的后续数据读出，其结果或将影响该疗法的未来发展方向。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.